---
schema_version: "secwatch.filing_event.v1"
accession: "0001549084-23-000018"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:54:15.069301+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics Q1 revenues hit record $4.1M, up 61% YoY; net loss narrows to $4.4M

## Summary
- Revenue of $4.1M, a 61% increase from $2.6M in Q1 2022; gross margin improved to 49% from 47%.
- Net loss of $4.4M ($0.33 per share) vs. $4.6M ($0.36 per share) in Q1 2022.
- Booked 23 EksoHealth devices in Q1; cash position $16.3M at March 31, 2023.
- Sales & marketing spend rose to $2.1M from $1.6M, reflecting HMC acquisition costs.
- CEO cites multi-unit orders with large network operators and Indego product line contributions.

## SEC filing metadata
- accession: 0001549084-23-000018
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000018/0001549084-23-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000018/ekso-20230427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549084-23-000018
- JSON: https://secwatch.observer/filing/0001549084-23-000018.json
- Plain text: https://secwatch.observer/filing/0001549084-23-000018.txt

## Key facts
- Earnings Releases
  EKSO BIONICS HOLDINGS, INC. reported three months ended March 31, 2023 results: revenue $4.1 million, net income $4.4 million, EPS $0.33 per basic and diluted share.
  - Period: three months ended March 31, 2023
  - Revenue: $4.1 million
  - Net income: $4.4 million
  - EPS: $0.33 per basic and diluted share
  - Result: reported results
  source text: for medical and industrial use, today reported financial results for the three months ended March 31, 2023. Recent Highlights and Accomplishments • Achieved record revenues of $4.1 million in the first quarter of 2023, up 61% from the first quarter of 2022 • Delivered products across continuum of care following the addition of the Indego ® product line • Booked a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000154908423000018/0001549084-23-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.